多巴丝肼片联合普拉克索治疗帕金森病的临床效果

多巴丝肼片联合普拉克索治疗帕金森病的临床效果

作者：徐珍

来源：《中外医学研究》2020年第08期

【摘要】目的：討论多巴丝肼片联合普拉克索治疗帕金森病的效果。方法：选择2018年1月-2019年2月笔者所在医院诊治的38例帕金森病患者为试验对象，按照随机原则分为试验组与对照组，每组19例。对照组仅采用多巴丝肼片治疗，试验组采用多巴丝肼片联合普拉克

索治疗。根据帕金森病统一评分量表（UPDRS）对两组治疗前后日常生活活动及运动功能进行评分，并对比两组治疗效果及不良反应发生率。结果：治疗前，两组UPDRSⅡ及UPDRSⅢ评分比较，差异均无统计学意义（P>0.05）。治疗后，试验组UPDRSⅡ及UPDRSⅢ评分均低于对照组，差异均有统计学意义（P<0.05）。试验组总有效率为100%，显著高于对照组的78.95%，差异有统计学意义（P<0.05）。两组头晕、恶心呕吐及嗜睡发生率比较，差异均无统计学意义（P>0.05）。试验组开关现象发生率明显低于对照组，差异有统计学意义

（P<0.05）。结论：多巴丝肼片联合普拉克索治疗帕金森病的效果较仅采用多巴丝肼片更显著，且开关现象发生率低，具有临床推广价值。

【关键词】多巴丝肼片普拉克索帕金森病

doi：10.14033/ki.cfmr.2020.08.056;;文献标识码 B;;文章编号 1674-6805（2020）08-0-03

Clinical Efficacy of Levodopa and Benserazide Tablet Combined with Pramipexole in the Treatment of Parkinson Disease/XU Zhen. //Chinese and Foreign Medical Research， 2020， 18（8）： -135

[Abstract] Objective： To discuss the clinical effect of Levodopa and Benserazide Tablet combined with Pramipexole in the treatment of Parkinson disease. Method： From January 2018 to February 2019， 38 patients with Parkinson disease diagnosed and treated in our hospital were selected as the subjects. According to the random principle， the patients were divided into the experimental group and the control group， 19 cases in each group. The control group was only treated with Levodopa and Benserazide Tablet， while the experimental group was treated with Levodopa and Benserazide Tablet combined with Pramipexole. According to the unified Parkinson disease rating scale （UPDRS）， activity of daily living and motor function of the two groups before and after treatment were scored， and the treatment effect and incidence of adverse reactions were compared between the two groups. Result： Before treatment， the scores of UPDRSⅡ and UPDRSⅢ were compared between the two groups， and the differences were not statistically significant （P>0.05）. After treatment， the scores of UPDRSⅡ and UPDRSⅢ in the experimental group were significantly lower than those of the control group， and the differences were statistically significant （P<0.05）. The total effective rate of the experimental group was 100%， which was higher than 78.95% of the control group， and the difference was statistically significant （P<0.05）. The incidences of dizziness， nausea and vomiting and drowsiness were compared between the two groups， and the differences were not statistically significant （P>0.05）. The incidence of switching phenomenon in the experimental group was lower than that of the control group， and the difference was statistically significant （P<0.05）. Conclusion： The effect of Levodopa and Benserazide Tablet combined with Pramipexole in the treatment of Parkinson disease is more significant than that of only using Levodopa and Benserazide Tablet， and the incidence of switching phenomenon is low， which has clinical value.